Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
Chubb
US Army
McKesson
Citi
Harvard Business School
QuintilesIMS
Farmers Insurance

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROXYUREA

« Back to Dashboard

Clinical Trials for Hydroxyurea

Trial ID Title Status Sponsor Phase Summary
NCT00000586 Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia.
NCT00000602 Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 To determine whether hydroxyurea prevents the onset of chronic end organ damage in young children with sickle cell anemia.
NCT00000623 Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed National Heart, Lung, and Blood Institute (NHLBI) N/A The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed Thalassemia Clinical Research Network N/A The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed New England Research Institutes N/A The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000916 A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 This study compares the safety and effectiveness of continuing your current anti-HIV medications to that of adding or switching some of your anti-HIV medications. It will follow the effect of these medication changes, including the addition of hydroxyurea (HU), on long-term viral suppression. Other medications which may be added include didanosine (ddI) and/or stavudine (d4T). Patients receiving combination antiretroviral therapy with indinavir (IDV), zidovudine (ZDV)(or d4T) and lamivudine (3TC) show viral suppression for two years or more. Discontinuation of one or two of these drugs results in prompt loss of the viral suppression. Other studies show that addition of HU to some reverse transcriptase inhibitor treatments results in increased antiviral effects. This study will provide further information on the effect of adding HU to a treatment regimen with respect to long-term viral suppression.
NCT00000919 A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A The purpose of this study is to compare the effectiveness of various combinations of anti-HIV drugs in HIV-positive men and women. Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV). Anti-HIV therapy is effective in preventing the spread of HIV in the body. However, patients often experience unpleasant side effects and have difficulties following the dosing schedule. This study looks for combinations of anti-HIV drugs ("cocktails") which will be the most effective with the fewest problems.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Hydroxyurea

Condition Name

Condition Name for Hydroxyurea
Intervention Trials
Sickle Cell Disease 39
Sickle Cell Anemia 27
HIV Infections 17
Polycythemia Vera 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydroxyurea
Intervention Trials
Anemia, Sickle Cell 76
Leukemia 29
Leukemia, Myeloid 29
Anemia 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydroxyurea

Trials by Country

Trials by Country for Hydroxyurea
Location Trials
United States 648
Italy 61
Germany 36
France 33
Spain 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydroxyurea
Location Trials
Illinois 43
New York 38
Texas 38
North Carolina 37
Maryland 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydroxyurea

Clinical Trial Phase

Clinical Trial Phase for Hydroxyurea
Clinical Trial Phase Trials
Phase 4 7
Phase 3 43
Phase 2/Phase 3 6
[disabled in preview] 148
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydroxyurea
Clinical Trial Phase Trials
Completed 93
Recruiting 48
Terminated 21
[disabled in preview] 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydroxyurea

Sponsor Name

Sponsor Name for Hydroxyurea
Sponsor Trials
National Cancer Institute (NCI) 24
National Heart, Lung, and Blood Institute (NHLBI) 20
Novartis Pharmaceuticals 15
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydroxyurea
Sponsor Trials
Other 244
Industry 87
NIH 65
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
Julphar
Moodys
AstraZeneca
Harvard Business School
Teva
Medtronic
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.